The pitch for a CJC-1295 ipamorelin blend is that two peptides acting on growth hormone release through different routes will produce a stronger combined effect. As a research question, that is reasonable. The problem is what happens next, when a plausible hormonal mechanism is presented as proof of muscle growth, fat loss, better sleep or faster recovery. Each of those benefits would need to be measured, and a rise in a hormone level cannot stand in for all of them. To judge the combination fairly, it helps to separate three things: what each compound does, what researchers have actually tested, and what people hope the pair will achieve.
What is CJC-1295?
CJC-1295 is a modified version of growth hormone releasing hormone, GHRH, the signal the brain uses to tell the pituitary gland to release growth hormone. The original molecule carries a chemical addition, the drug affinity complex or DAC, that lets it bind to albumin in the blood. Attaching a drug to albumin is a way of keeping it in circulation longer, and it gives CJC-1295 with DAC a half life of about a week.
CJC-1295 is not growth hormone. It works upstream, prompting the body to release its own growth hormone rather than supplying the hormone directly. That explains the mechanism. It does not tell you whether turning up the signal produces a useful result in a particular person.
Why "with DAC" and "without DAC" matter
Products are often sold as CJC-1295 without DAC, also called modified GRF (1-29). This is not a branding detail. The DAC was designed to change how long the molecule lasts, and removing it gives a short acting compound with a completely different exposure profile.
The human studies of CJC-1295 used the long acting version with DAC. No clinical trial of the version without DAC has ever been published, in people or in animals, so the week long half life and the hormone results from the published studies do not transfer to it. When an article quotes those figures while describing the version without DAC, it is borrowing evidence from a different molecule.
What is ipamorelin?
Ipamorelin is a five amino acid growth hormone secretagogue, which simply means something that prompts the release of a substance. It works through a different receptor from CJC-1295: the ghrelin receptor rather than the GHRH receptor. Novo Nordisk developed it in the 1990s, and the founding paper called it the first selective growth hormone secretagogue because, unlike earlier compounds of its kind, it released growth hormone in animals without also raising the stress hormones ACTH and cortisol Animal 1.
So the pairing has a plausible basis: two different signalling routes into the same hormone system. Whether that improves any outcome people care about is a separate question.
What did the human CJC-1295 studies find?
A 2006 paper reported two randomised, placebo controlled, double blind studies in healthy adults aged 21 to 61, lasting 28 and 49 days Human 2. Single injections raised average growth hormone levels two to tenfold for six days or more, and IGF-1, a hormone produced in response to growth hormone, rose one and a half to threefold for nine to eleven days. The estimated half life was 5.8 to 8.1 days. A second study with frequent blood sampling found that the natural pulses of growth hormone release carried on during treatment 3.
That is good evidence that this preparation changed hormone levels in people. But every outcome in those studies was a hormone level or a measure of how the drug behaved. None measured muscle, strength, body fat, sleep or injury healing. Clinical development of CJC-1295 was abandoned in 2006, and no efficacy trial has ever been published. The paper deserves credit for the question it answered; it cannot be used to answer questions it did not test.
What has ipamorelin been studied for in people?
A human study in healthy men confirmed that ipamorelin triggers a burst of growth hormone release, with a short half life of about two hours and a response that varied a lot from person to person Human 4. That supports calling it biologically active. It does not establish a muscle building effect.
The only properly randomised trial of ipamorelin tested something quite different: postoperative ileus, the slow return of bowel function after abdominal surgery Human 5. It enrolled 117 people having bowel operations, 114 of whom were treated. The median time to the first tolerated meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, but the difference was not statistically significant, and there were no significant differences in the other efficacy measures. Development was then discontinued.
The word recovery needs context here. Recovery of bowel function after surgery is not recovery after training, a healed tendon or better sleep after exercise, and a trial in one setting does not support claims in the others.
Has the blend itself been tested?
No convincing randomised human trial of the combination has been published. The studies above tested each compound on its own, and that stays true when both papers appear in the same reference list.
A combined product raises new questions about exposure, interaction, tolerability and outcomes that evidence on each part cannot answer. A useful trial would name the exact forms used, test the actual blend against each component and an inactive control, and measure the benefit being claimed. It would also say who was studied, whether healthy adults, older adults or people with a diagnosed hormone disorder, because a result in one group does not justify a claim about another. Without that trial, a description of two mechanisms is a reason to do research, not a validated treatment.
Hulk Stack (CJC-1295 with DAC + ipamorelin)
The only stack with a real mechanism behind it, since these two drug types genuinely release more growth hormone together than apart in humans. But that was shown with different molecules in one off laboratory tests, and nobody has ever trialled this exact pair.
Combination evidence. Tier 2: human acute mechanistic data supports GHRH-plus-GHRP synergy as a drug class, but no trial has tested this specific pairing or any chronic outcome
Does higher growth hormone mean more muscle?
Not by itself. A hormone level tells researchers about a biological response. Showing a muscle building benefit would need measurements of muscle or body composition, ideally with strength and function alongside. The same goes for fat loss: a change in IGF-1 says nothing about how much body fat someone lost. And a claim about better sleep needs sleep outcomes, not an assumption that a hormonal change must have improved it.
Blood results look precise. They come with a number, units and a reference range, which makes them feel more definitive than they may be for the question at hand. Precise measurement is not the same as relevance to the promised benefit.
Does stimulating the body's own hormones make it safer?
It does not establish safety. That the body makes the hormone explains where it comes from, not whether deliberately changing how much is released, when and for how long, is appropriate. Plenty of medicines act through natural receptors and still need careful testing. The relevant questions are what changes, by how much, for how long and with what consequences, and a bigger hormonal response is not automatically a better or safer one.
What is known about side effects?
The CJC-1295 studies were short, and while they reported no serious reactions in that window, they cannot establish long term safety or the safety of a combination. The US FDA has said it identified serious adverse events with CJC-1295, including increased heart rate and a whole body vasodilatory reaction, and that the available clinical data are limited 6. For ipamorelin it has raised concerns about immune reactions linked to impurities, and about how hard the product is to characterise because it contains unnatural amino acids. Its entry also refers to a published report of serious adverse events, including a death, when ipamorelin was given intravenously to improve gastric motility. Both substances have since been withdrawn from the FDA's category 2 list for pharmacy compounding because their nominations were withdrawn, which is a procedural step, not a finding of safety.
Ipamorelin's selectivity also has limits. It describes how the compound behaved against other hormones in the conditions tested, which helps explain why it was worth developing. It is not a guarantee of no other effects in every person, product or combination. The fair conclusion is that the risk profile has not been established for the uses claimed for the blend.
What about competitive sport?
Both are banned at all times under section S2.2.4 of the 2026 WADA Prohibited List, which names CJC-1295 among the GHRH analogues and ipamorelin among the growth hormone secretagogues 7. That is a clear rule for athletes, but it is not evidence that the combination works. Anti doping status and proven benefit are different questions.
What should a useful article about the combination tell you?
It should say exactly which CJC-1295 is meant, with or without DAC, and keep the evidence for CJC-1295, for ipamorelin and for the combination separate. It should distinguish the proposed mechanism from the outcomes actually measured. If the claim is muscle growth, look for muscle outcomes; if it is fat loss, sleep or recovery, look for those, in a relevant group of people. An accurate account of the receptors can sit alongside a clinical claim that is still unsupported.
CJC-1295 with DAC
Limited evidenceGH secretagogues · 3 cited studies
Human data consist of two small, short, sponsor run pharmacodynamic studies in healthy volunteers measuring only growth hormone and IGF-1; the only other citation is a mouse study, no efficacy trial has ever been completed or published, and the single phase 2 trial was halted and never reported.
UK status. No UK marketing authorisation.
CJC-1295 without DAC
Preclinical onlyGH secretagogues · 2 cited studies
No study of this exact molecule has been identified in humans or animals; its properties are inferred entirely from sermorelin and from the CJC-1295 chemistry programme, so it sits at the floor of the scale: 'preclinical' overstates it, since there is not even a published animal study.
UK status. No UK marketing authorisation.
Ipamorelin
Limited evidenceGH secretagogues · 4 cited studies
Human data comprise a single phase 1 pharmacokinetic study and one well conducted phase 2 randomised trial in postoperative ileus that missed its primary endpoint (P=0.15) and all secondary endpoints; the remaining citations are preclinical, and there is no controlled human data of any kind for body composition, recovery or the other uses for which it is marketed.
UK status. No UK marketing authorisation.
The BioRx conclusion
CJC-1295 and ipamorelin are real molecules with real pharmacology behind them. The evidence usually offered for pairing them, though, concerns each compound on its own, hormone measurements and particular experimental settings, not a proven approach to muscle gain, fat loss, sleep or injury recovery. A plausible combination is not the same as a proven one. The useful next step is not a more persuasive explanation of why the blend should work, but a trial showing whether it delivers meaningful benefits, for whom, and at what risk.
Frequently asked questions
Has CJC-1295 with ipamorelin been tested in a clinical trial?
Not in a convincing randomised trial of the combination for muscle, fat loss, sleep or recovery. Each compound has been studied on its own, for hormone levels and, in ipamorelin's case, bowel recovery after surgery.
What is the difference between CJC-1295 with and without DAC?
The DAC lets CJC-1295 bind albumin and last about a week. The version without it, also called modified GRF (1-29), is short acting and has never been tested in a published clinical trial.
Does ipamorelin build muscle?
That has not been shown. Human studies confirm it releases growth hormone, but none measured muscle, and its only randomised trial, in bowel surgery, did not meet its main goal.
Are CJC-1295 and ipamorelin legal in the UK?
Neither has a UK marketing authorisation, and supplying either for human use is unlawful under the Human Medicines Regulations 2012. Both are banned in sport.
References
Studies marked "View study in BioRx" sit in the clinical studies index with their design and evidence grade.
- Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology.PubMed · DOI · View study in BioRx
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism.PubMed · DOI · View study in BioRx
- Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism.PubMed · DOI · View study in BioRx
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research.PubMed · DOI · View study in BioRx
- Beck DE, Sweeney WB, McCarter MD (Ipamorelin 201 Study Group) (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease.PubMed · DOI · ClinicalTrials.gov · View study in BioRx
- FDA, Certain bulk drug substances for use in compounding that may present significant safety risks
- WADA, 2026 Prohibited List
